COR Therapeutics ( CORR) posted a first-quarter loss of 5 cents a share, a penny better than analysts had expected.

In the year-earlier period, the biotech posted a loss of 19 cents a share. Revenue climbed 27% to $22.8 million from $17.9 million.

The company also again said it expects to earn 35 cents to 37 cents a share this year. Analysts expect that it'll earn 34 cents a share, according to Thomson Financial/First Call.

If you liked this article you might like

Spain to Play Netherlands for World Cup

Spain to Play Netherlands for World Cup

Wal-Mart: Analysts' Upgrades, Downgrades

Wal-Mart: Analysts' Upgrades, Downgrades

Netherlands Advances to World Cup Final

Netherlands Advances to World Cup Final

Apple: Analysts' Upgrades, Downgrades

Apple: Analysts' Upgrades, Downgrades

World Markets Mostly Lower Monday

World Markets Mostly Lower Monday